Biotech

Biotech Allison DeAngelis

STAT Plus: A new cell therapy company takes its vision from four founders, and its skin from George Church

Biotech Elaine Chen

STAT Plus: Corbus sees Novo’s controversial obesity approach as a ticket to a blockbuster

Biotech Jason Mast

STAT Plus: In race to make gene therapy for age-related blindness, 4D Molecular announces positive results

Biotech Jonathan Wosen

STAT Plus: Biotech feud over the multibillion-dollar cancer blood test market spills onto social media

The Readout Elaine Chen

STAT Plus: Bernie Sanders keeps the heat on Novo’s high prices

Biotech Allison DeAngelis

STAT Plus: Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion

The Readout Elaine Chen

STAT Plus: FDA formalizes protocol for international cancer trials

Who to Know Meghana Keshavan

STAT Plus: 12 people shaping psychedelics drug development

Pharma Andrew Joseph

STAT Plus: The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more

Biotech Andrew Joseph

STAT Plus: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do

The Readout Meghana Keshavan

STAT Plus: The essential biotech updates of the day

Biotech Jonathan Wosen

STAT Plus: Genentech, a biotech with a storied past, confronts new turbulence in the present

Biotech Jonathan Wosen

STAT Plus: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending

Biotech Andrew Joseph

STAT Plus: News from ESMO: An AstraZeneca win in bladder cancer, and more

Biotech Andrew Joseph

STAT Plus: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study 

Biotech Andrew Joseph

STAT Plus: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial

Biotech Andrew Joseph

STAT Plus: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness

Biotech Andrew Joseph

STAT Plus: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target

The Readout Elaine Chen

STAT Plus: Can GLP-1 drugs help with type 1 diabetes?

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Can iTeos and GSK solve TIGIT’s troubles?

The Readout Elaine Chen

STAT Plus: Moderna cuts spending, and Sarepta’s ‘curse’ on Califf

Biotech Elaine Chen

STAT Plus: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial

Biotech Matthew Herper and Jason Mast

STAT Plus: Moderna touts research progress as it cuts R&D spending by $1.1 billion

Biotech Jason Mast and John Wilkerson

STAT Plus: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire

Biotech Brittany Trang

STAT Plus: ‘Sarepta’s like a curse on me’: FDA commissioner dismisses controversy over Elevidys

The Readout Meghana Keshavan

STAT Plus: Eli Lilly releases new data on weekly insulin

Biotech Jonathan Wosen

STAT Plus: After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives

Biotech Elaine Chen

STAT Plus: Novo Nordisk’s amylin pill leads to substantial weight loss in early study

The Readout Meghana Keshavan

STAT Plus: Five biotech news stories you need to read today